|Videos|April 9, 2013
Episode 18 - Impact of Obesity on Cardiometabolic Events
Advertisement
Episodes in this series
During this segment, Michael Weber, MD, explores obesity and its impact on cardiovascular health outcomes.
Dr Weber believes that it is difficult to conclude whether or not managing obesity will effectively provide better results, as no definitive clinical trials have tested this theory. He explains that there is no current evidence that reveals that a reduction in weight will reduce the number of strokes, heart attacks, or other events.
Regardless, Dr Weber still feels that physicians should practice reducing patients’ body mass indexes to help lower the risk for developing cardiovascular events.
Advertisement
Related to this article
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.
Cost and access, not side effects, drive GLP-1 discontinuation, and obesity should be covered like diabetes, says Fatima Cody Stanford, MD.
At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.
A poster at the ASCO Quality Care Symposium describes how a value-based care partnership used prior authorization data and pharmacist workflows to move eligible patients off flat dosing of pembrolizumab.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?
5